CollPlant to Acquire Nano-X Imaging for $126M
Ticker: CLGN · Form: 6-K · Filed: Aug 19, 2024 · CIK: 1631487
Sentiment: mixed
Topics: acquisition, merger, healthcare, biotechnology
TL;DR
CollPlant buying Nano-X for $126M cash/stock, closing Q4'24. Big medtech combo incoming.
AI Summary
CollPlant Biotechnologies Ltd. announced on August 19, 2024, that it has entered into a binding agreement to acquire Nano-X Imaging Ltd. for approximately $126 million in cash and stock. The acquisition is expected to close in the fourth quarter of 2024, subject to customary closing conditions and shareholder approval.
Why It Matters
This strategic acquisition aims to create a comprehensive medical imaging and regenerative medicine company, potentially impacting the healthcare landscape by integrating advanced imaging technology with bioprinting solutions.
Risk Assessment
Risk Level: medium — The acquisition is subject to shareholder approval and customary closing conditions, introducing uncertainty regarding its completion.
Key Numbers
- $126M — Acquisition Value (Total consideration for Nano-X Imaging Ltd.)
Key Players & Entities
- CollPlant Biotechnologies Ltd. (company) — Acquiring company
- Nano-X Imaging Ltd. (company) — Target company
- $126 million (dollar_amount) — Acquisition price
- fourth quarter of 2024 (date) — Expected closing period
FAQ
What is the total value of the proposed acquisition of Nano-X Imaging Ltd. by CollPlant Biotechnologies Ltd.?
The total value of the proposed acquisition is approximately $126 million.
What is the expected closing timeframe for the acquisition?
The acquisition is expected to close in the fourth quarter of 2024.
What are the primary components of the acquisition consideration?
The consideration will be paid in a combination of approximately $126 million in cash and stock.
What are the conditions for the closing of the acquisition?
The closing is subject to customary closing conditions and shareholder approval.
What is the strategic rationale behind this acquisition for CollPlant?
The acquisition aims to create a comprehensive medical imaging and regenerative medicine company.
Filing Stats: 281 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-08-19 08:34:33
Filing Documents
- ea0211718-6k_collplant.htm (6-K) — 10KB
- ea021171801ex99-1_collplant.htm (EX-99.1) — 25KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- ex99-1_002.jpg (GRAPHIC) — 3KB
- 0001213900-24-070437.txt ( ) — 45KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. COLLPLANT BIOTECHNOLOGIES LTD. Date: August 19, 2024 By: /s/ Eran Rotem Name: Eran Rotem Title: Deputy CEO and Chief Financial Officer 2